NasdaqGS - Nasdaq Real Time Price USD

Mind Medicine (MindMed) Inc. (MNMD)

8.52

0.00

(0.00%)

At close: April 26 at 4:00 PM EDT

8.50

-0.02

(-0.24%)

After hours: April 26 at 7:36 PM EDT

MindMed to Present at Upcoming May Medical Conferences

NEW YORK, April 25, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:

Business Wire yesterday

MNMD
0.00%
MindMed to Present at Upcoming April Medical Conferences

NEW YORK, April 02, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:

Business Wire 24 days ago

MNMD
0.00%
MindMed Announces Voluntary Delisting from Cboe Canada

NEW YORK, April 01, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed’s common shares will continue to be liste

Business Wire 25 days ago

MNMD
0.00%
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference

NEW YORK, March 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024.

Business Wire last month

MNMD
0.00%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Key Takeaways; Psychedelic Sector In a rollercoaster week for MSOs, the cannabis industry faced both triumphs and challenges. Despite many positive Q4 reports in late February, this week witnessed an unusual trend as only a few large MSO reported their financials. Surprisingly, the market responded with increased selling even after companies […]

Market Exclusive last month

MNMD
0.00%
CRON

AFCG
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

NEW YORK, March 07, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 per common share. In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,50

Business Wire last month

MNMD
0.00%
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

NEW YORK, March 07, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD). The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 1

Business Wire last month

MNMD
0.00%
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

NEW YORK, March 01, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in Generalized Anxiety Disorder (GAD), including 12-week topline safety, efficacy, and durability results from the Company’s Phase 2b trial

Business Wire last month

MNMD
0.00%
MindMed Reports 2023 Financial Results and Business Updates

NEW YORK, February 28, 2024--Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.

Business Wire last month

MNMD
0.00%
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update

NEW YORK, February 22, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, February 28, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company’s results for the year ended December 31, 2023.

Business Wire 2 months ago

MNMD
0.00%
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference

NEW YORK, February 07, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference:

Business Wire 2 months ago

MNMD
0.00%
MindMed Announces Business Update and Anticipated Milestones for 2024

NEW YORK, January 08, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today provided a corporate update and outlook for 2024.

Business Wire 3 months ago

MNMD
0.00%
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

NEW YORK, December 14, 2023--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-depend

Business Wire 4 months ago

MMDCF

MNMD
0.00%
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

NEW YORK, November 02, 2023--MindMed today reported its financial results for the quarter ended September 30, 2023.

Business Wire 5 months ago

MNMD
0.00%
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update

NEW YORK, October 26, 2023--MindMed plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET.

Business Wire 5 months ago

MNMD
0.00%
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

NEW YORK, October 24, 2023--Enrollment completed for MMED007, the Phase 2a study evaluating repeated low-dose administration of MM-120 for the treatment of adults with ADHD.

Business Wire 5 months ago

MNMD
0.00%
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress

NEW YORK, October 03, 2023--MindMed will present preclinical data for MM-402 in a model for autism spectrum disorder.

Business Wire 6 months ago

MNMD
0.00%
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

NEW YORK, September 14, 2023--MindMed will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit.

Business Wire 7 months ago

MNMD
0.00%
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

NEW YORK, September 12, 2023--MindMed has completed enrollment and dosing in Study MMED008, the Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.

Business Wire 7 months ago

MNMD
0.00%
MindMed to Participate at September Investor Conferences

NEW YORK, August 28, 2023--The MindMed management team will participate in two September investor conferences.

Business Wire 7 months ago

MNMD
0.00%

Performance Overview

Return	MNMD	S&P 500
YTD	+132.79%	+6.92%
1-Year	+136.01%	+25.26%
3-Year	-83.86%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mind Medicine (MindMed) Inc. (MNMD)

MindMed to Present at Upcoming May Medical Conferences

MindMed to Present at Upcoming April Medical Conferences

MindMed Announces Voluntary Delisting from Cboe Canada

MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

MindMed Reports 2023 Financial Results and Business Updates

MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update

MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference

MindMed Announces Business Update and Anticipated Milestones for 2024

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update

MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress

MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

MindMed to Participate at September Investor Conferences

Performance Overview